Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · IEX Real-Time Price · USD
2.630
+0.130 (5.20%)
At close: May 2, 2024, 4:00 PM
2.670
+0.040 (1.52%)
After-hours: May 2, 2024, 5:08 PM EDT
Vivos Therapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Vivos Therapeutics.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for VVOS.
Recommendation Trends
Rating | Aug '22 | Sep '22 | Oct '22 | Nov '22 | Dec '22 | Jan '23 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $63 | Strong Buy | Initiates | $63 | +2,276.43% | Jan 17, 2023 |
Roth Capital | Roth Capital | Strong Buy Maintains $275 → $250 | Strong Buy | Maintains | $275 → $250 | +9,405.70% | Aug 13, 2021 |
Roth Capital | Roth Capital | Strong Buy Maintains $300 → $275 | Strong Buy | Maintains | $300 → $275 | +10,356.27% | May 18, 2021 |
Craig-Hallum | Craig-Hallum | Strong Buy Initiates $300 | Strong Buy | Initiates | $300 | +11,306.84% | Jan 11, 2021 |
Roth Capital | Roth Capital | Strong Buy Initiates $300 | Strong Buy | Initiates | $300 | +11,306.84% | Jan 5, 2021 |
Financial Forecast
Revenue This Year
17.59M
from 13.80M
Increased by 27.48%
Revenue Next Year
19.60M
from 17.59M
Increased by 11.40%
EPS This Year
-3.47
from -11.14
EPS Next Year
-1.53
from -3.47
Revenue Forecast
Revenue | 2024 | 2025 |
---|---|---|
High | 19.4M | 20.2M |
Avg | 17.6M | 19.6M |
Low | 15.7M | 18.8M |
Revenue Growth
Revenue Growth | 2024 | 2025 |
---|---|---|
High | 40.8% | 14.7% |
Avg | 27.5% | 11.4% |
Low | 13.6% | 7.0% |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | -2.99 | -1.58 |
Avg | -3.47 | -1.53 |
Low | -3.87 | -1.47 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.